Trial Profile
Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs ACTR 087/Rituximab combination therapy (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Acronyms ATTCK20-2
- Sponsors Cogent Biosciences
- 27 Mar 2020 Status changed from suspended to completed.
- 12 Nov 2019 According to an Unum Therapeutics media release, data from this trial will be presented at the American Society of Hematology (ASH) Annual Meeting, December 7-10, Orlando, FL.
- 06 Nov 2019 Results released in the 61st Annual Meeting and Exposition of the American Society of Hematology.